iShares MSCI China ETF vs NeoGenomics Inc. Common Stock — how do they compare? iShares MSCI China ETF trades at $51.22 (market cap $5.82B), while NeoGenomics Inc. Common Stock trades at $17 (market cap $2.17B). The key difference: iShares MSCI China ETF is far larger — about 2.7× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 65 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| MCHI | NEO | |
|---|---|---|
Market Cap | $5.82B | $2.17B |
Volume | 1,436,013 | 1,615,943 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $19.91 |
52-Week Low | $50.48 | $7.19 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | — | $2.47B |
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $52.135, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and weak domestic consumption, though corporate profits surged 26% in Q2. Recent news highlights potential trade developments from upcoming U.S.-China talks and concerns over export controls on AI and semiconductors.
The outlook remains cautious with significant discount to US indices offering potential value, but risks from global trade tensions and China's economic rebalancing persist. Institutional activity shows mixed positioning, with some funds increasing stakes while others reduce exposure, reflecting uncertainty in Chinese equity markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →